Effects of HIV protease inhibitors on cardiac conduction velocity in unselected HIV-infected patients

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 3, 2011, Pages 442-448

  Charbit, B ^a,b,c   Gayat, E ^d   Voiriot, P ^e   Boccara, F ^b,d   Girard, P M ^b,c   Funck Brentano, C ^a,b,c  

^a Institute OfCardiometabolism and Nutrition   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSERM   (France)

^e Cardiabase   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ARTICLE; ATRIOVENTRICULAR BLOCK; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART BUNDLE BRANCH BLOCK; HEART CONDUCTION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PR INTERVAL; PREVALENCE; PRIORITY JOURNAL; QRS COMPLEX; SIDE EFFECT;

ATRIOVENTRICULAR BLOCK; BUNDLE-BRANCH BLOCK; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEART CONDUCTION SYSTEM; HEART FAILURE; HEART RATE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MYOCARDIAL ISCHEMIA;

EID: 80052029580     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.131     Document Type: Article

References (37)

1. Gianotti, N. et al. Electrocardiographic changes in HIV-infected, drugexperienced patients being treated with atazanavir. AIDS 21, 1648-1651 (2007). (Pubitemid 47075490)
2. Busti, A.J. et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med. 7, 317-322 (2006). (Pubitemid 43805692)
3. Mymin, D., Mathewson, F.A., Tate, R.B. & Manfreda, J. The natural history of primary first-degree atrioventricular heart block. N. Engl. J. Med. 315, 1183-1187 (1986). (Pubitemid 17056648)
4. Bexton, R.S. & Camm, A.J. First degree atrioventricular block. Eur. Heart J. 5 (suppl. A), 107-109 (1984). (Pubitemid 14105259)
5. Cheng, S. et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA 301, 2571-2577 (2009).
6. Currier, J.S. et al.; Working Group 2. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 118, e29-e35 (2008).
7. Lang, S. et al.; French Hospital Database on HIV-ANRS CO4. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 24, 1228-1230 (2010).
8. Lu, H.R., Rohrbacher, J., Vlaminckx, E., Van Ammel, K., Yan, G.X. & Gallacher, D.J. Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers. Br. J. Pharmacol. 160, 60-76 (2010).
9. Nattel, S. Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovasc. Res. 37, 567-577 (1998). (Pubitemid 28231151)
10. Greenberg, H.M., Dwyer, E.M. Jr, Hochman, J.S., Steinberg, J.S., Echt, D.S. & Peters, R.W. Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. Br. Heart J. 74, 631-635 (1995). (Pubitemid 26004633)
11. Hondeghem, L.M. Antiarrhythmic agents: modulated receptor applications. Circulation 75, 514-520 (1987). (Pubitemid 17026039)
12. S oliman, E.Z. et al.; INSIGHT SMART Study Group. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 25, 367-377 (2011).
13. Grant, A. & Chauhan, V. Mode of action of antiarrhythmic drugs. In Heart Physiology and Pathophysiology 4th edn (eds. Kurachi, Y., Sperelakis, N., Terzic, A. & Cohen, M.) 837-849 (Academic Press, San Diego, CA, 2001).
14. S ingh, B.N. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility. J. Cardiovasc. Electrophysiol. 10, 283-301 (1999). (Pubitemid 29115254)
15. S arapa, N., Nickens, D.J., Raber, S.R., Reynolds, R.R. & Amantea, M.A. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. Clin. Pharmacol. Ther. 83, 153-159 (2008).
16. Carruthers, S.G., McCall, B., Cordell, B.A. & Wu, R. Relationships between heart rate and PR interval during physiological and pharmacological interventions. Br. J. Clin. Pharmacol. 23, 259-265 (1987). (Pubitemid 17108185)
17. Malik, M., Hnatkova, K., Sisakova, M. & Schmidt, G. Subject-specific heart rate dependency of electrocardiographic QT, PQ, and QRS intervals. J. Electrocardiol. 41, 491-497 (2008).
18. Liu, S., Yuan, S., Kongstad, O. & Olsson, S.B. Gender differences in the electrophysiological characteristics of atrioventricular conduction system and their clinical implications. Scand. Cardiovasc. J. 35, 313-317 (2001). (Pubitemid 34100811)
19. Mason, J.W., Ramseth, D.J., Chanter, D.O., Moon, T.E., Goodman, D.B. & Mendzelevski, B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J. Electrocardiol. 40, 228-234 (2007).
20. Zerkiebel, N. et al. Electrocardiographic findings in a middle-aged African population in the Seychelles islands. J. Electrocardiol. 33, 1-15 (2000). (Pubitemid 30080219)
21. Fleg, J.L., Das, D.N., Wright, J. & Lakatta, E.G. Age-associated changes in the components of atrioventricular conduction in apparently healthy volunteers. J. Gerontol. 45, M95-100 (1990). (Pubitemid 20171155)
22. Frank, S., Colliver, J.A. & Frank, A. The electrocardiogram in obesity: statistical analysis of 1,029 patients. J. Am. Coll. Cardiol. 7, 295-299 (1986). (Pubitemid 16164410)
23. D'Agostino, R.B. Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat. Med. 17, 2265-2281 (1998). (Pubitemid 28466823)
24. Chaubey, S.K., Sinha, A.K., Phillips, E., Russell, D.B. & Falhammar, H. Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection. Sex. Health 6, 254-257 (2009).
25. Madias, J.E. Drug-induced QRS morphology and duration changes. Cardiol. J. 15, 505-509 (2008).
26. T he Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 321, 406-12 (1989).
27. Haverkamp, W., Hindricks, G., Fechtrup, C., Borggrefe, M. & Breithardt, G. Sodium channel blockers in the treatment of ventricular arrhythmias: different effects in the normal, ischaemic or failing heart? Eur. Heart J. 12 (suppl. F), 10-17 (1991).
28. Flaker, G.C., Blackshear, J.L., McBride, R., Kronmal, R.A., Halperin, J.L. & Hart, R.G. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J. Am. Coll. Cardiol. 20, 527-532 (1992).
29. Gottlieb, S.S., Kukin, M.L., Medina, N., Yushak, M. & Packer, M. Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure. Circulation 81, 860-864 (1990). (Pubitemid 20090382)
30. Ravid, S., Podrid, P.J., Lampert, S. & Lown, B. Congestive heart failure induced by six of the newer antiarrhythmic drugs. J. Am. Coll. Cardiol. 14, 1326-1330 (1989). (Pubitemid 19268687)
31. Weirich, J. & Antoni, H. Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs. Basic Res. Cardiol. 93 (suppl. 1), 125-132 (1998). (Pubitemid 28499479)
32. Ranger, S., Talajic, M., Lemery, R., Roy, D., Villemaire, C. & Nattel, S. Kinetics of use-dependent ventricular conduction slowing by antiarrhythmic drugs in humans. Circulation 83, 1987-1994 (1991).
33. Ranger, S., Talajic, M., Lemery, R., Roy, D. & Nattel, S. Amplification of flecainideinduced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade. Circulation 79, 1000-1006 (1989). (Pubitemid 19129180)
34. S adowski, Z.P. et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. Am. Heart J. 137, 792-798 (1999). (Pubitemid 29226287)
35. Boccara, F. et al.; Prognosis of Acute Coronary Syndrome in HIV-infected patients (PACS) Investigators. Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. Eur. Heart J. 32, 41-50 (2011).
36. Desai, A.D., Yaw, T.S., Yamazaki, T., Kaykha, A., Chun, S. & Froelicher, V.F. Prognostic Significance of Quantitative QRS Duration. Am. J. Med. 119, 600-606 (2006). (Pubitemid 44041255)
37. Charbit, B. et al. Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study. Br. J. Clin. Pharmacol. 67, 76-82 (2009).